Opinion

Video

Clinical Scenario I: 68-yr Old Man with Early Relapse MM

Author(s):

Robert Z. Orlowski, MD, PhDJonathan L. Kaufman, MD

Key opinion leaders present a clinical patient scenario involving a 68-year-old male patient presenting with early relapse multiple myeloma.

Related Videos
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
Sagar Lonial, MD, FACP
1 KOL is featured in this series.
Related Content
FDA
September 17th 2024

FDA Grants RMAT Designation to P-BCMA-ALL01 for R/R Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Sagar Lonial, MD, FACP
September 13th 2024

Myeloma Molecular Profiling Reveals Unique Copy Number and Expression Subtypes

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Meletios A. Dimopoulos, MD, professor, chairman, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine
September 6th 2024

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.
September 6th 2024

FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL